Streetwise Reports (12/05/2019)
Shares of Aurinia Pharmaceuticals traded much higher after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20.
read more >